| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
InnoCare Pharma Limited (HK: 9969)
9969 Technical Analysis
5
| As on 12th Sep 2025 9969 STOCK Price closed @ 19.19 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.53 & Strong Buy for SHORT-TERM with Stoploss of 4.75 we also expect STOCK to react on Following IMPORTANT LEVELS. |
9969STOCK Price
| Open | 16.90 | Change | Price | % |
| High | 19.67 | 1 Day | 2.37 | 14.09 |
| Low | 16.90 | 1 Week | 0.73 | 3.95 |
| Close | 19.19 | 1 Month | 1.61 | 9.16 |
| Volume | 42508000 | 1 Year | 14.30 | 292.43 |
| 52 Week High 20.00 | 52 Week Low 4.06 | ||||
HK Hong Kong Most Active Stocks
| 0020 | 2.26 | 7.11% |
| 0020-OL | 2.26 | 7.11% |
| CSHK100 | 2354.52 | 1.46% |
| 2007 | 0.66 | 6.45% |
| 1918 | 1.87 | 8.72% |
| 6666 | 1.11 | 20.65% |
| 1341 | 0.28 | -6.67% |
| 43 | 1.14 | 0.00% |
| 3377 | 0.17 | 13.33% |
| 0813 | 0.42 | 2.44% |
HK Hong Kong Top Gainers Stocks
HK Hong Kong Top Losers Stocks
| 9969 Daily Charts |
9969 Intraday Charts |
Whats New @ Bazaartrend |
9969 Free Analysis |
|
|
9969 Important Levels Intraday
| RESISTANCE | 24.53 |
| RESISTANCE | 22.82 |
| RESISTANCE | 21.76 |
| RESISTANCE | 20.70 |
| SUPPORT | 17.68 |
| SUPPORT | 16.62 |
| SUPPORT | 15.56 |
| SUPPORT | 13.85 |
9969 Forecast September 2025
| 4th UP Forecast | 21.79 |
| 3rd UP Forecast | 20.96 |
| 2nd UP Forecast | 20.44 |
| 1st UP Forecast | 19.93 |
| 1st DOWN Forecast | 18.45 |
| 2nd DOWN Forecast | 17.94 |
| 3rd DOWN Forecast | 17.42 |
| 4th DOWN Forecast | 16.59 |
9969 Weekly Forecast
| 4th UP Forecast | 20.13 |
| 3rd UP Forecast | 19.83 |
| 2nd UP Forecast | 19.64 |
| 1st UP Forecast | 19.46 |
| 1st DOWN Forecast | 18.92 |
| 2nd DOWN Forecast | 18.74 |
| 3rd DOWN Forecast | 18.55 |
| 4th DOWN Forecast | 18.25 |
9969 Forecast2025
| 4th UP Forecast | 51.16 |
| 3rd UP Forecast | 40.91 |
| 2nd UP Forecast | 34.57 |
| 1st UP Forecast | 28.23 |
| 1st DOWN Forecast | 10.15 |
| 2nd DOWN Forecast | 3.81 |
| 3rd DOWN Forecast | -2.53 |
| 4th DOWN Forecast | -12.78 |
InnoCare Pharma Limited ( HK Hong Kong Symbol : 9969 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
9969 Business Profile
InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China. Address: Zhongguancun Life Science Park, Beijing, China, 102206
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service